Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 2022 Global Investment Conference on May 23-26

News provided by

May 19, 2022, 09:30 ET

SALT LAKE CITY, May 19, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the H.C. Wainwright & Co. 2022 Global Investment Conference, being held in-person and virtually on May 23-26 in Miami, Florida.

Dwight Egan, Company CEO, will be conducting a presentation discussing recent Company performance as well as its forthcoming Co-Dx PCR Home Diagnostic Platform. The presentation can be accessed by clicking here or through the Events and Webcasts section of the Co-Diagnostics website on May 25, 2022 at 1:30 PM Eastern Time, for institutional investors and industry professionals who have registered for the event.

Dwight Egan, Co-Diagnostics Chief Executive Officer, remarked "Florida has represented an important market for Co-Dx since the early days of the COVID-19 pandemic, with several world-class distributors and laboratory facilities operating across the state contributing over $28 million dollars of revenue. Our mosquito abatement vertical has also grown steadily in the state since 2019, with additional full laboratory installations taking place in Florida and the surrounding region this year. We are looking forward to the opportunity to communicate our past success and future ambitions with our investor base at the H.C. Wainwright conference in Miami next week."

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things: our products may not prove to be as effective as other products currently being commercialized or to be commercialized in the future by competitors; risks inherent in manufacturing and scaling up to commercial quantities while maintaining quality controls; the uncertainties inherent in new product development, including the cost and time required to gain regulatory clearance for such product and to commercialize such product(s);and, market acceptance of our products once commercialized. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations, and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in the Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 25, 2021, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

SOURCE Co-Diagnostics